IMAB – I-Mab ADR
I-MABIMAB
$5.09Name : I-MAB
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $415,650,944.00
EPSttm : -0.55
I-MAB
$5.09
8.07%$0.38Float Short %
0.8
Margin Of Safety %
Put/Call OI Ratio
0.19
EPS Next Q Diff
EPS Last/This Y
0.05
EPS This/Next Y
-0.1
Price
5.18
Target Price
6.2
Analyst Recom
1
Performance Q
384.76
Relative Volume
1.8
Beta
1.23
Ticker: IMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | IMAB | 2.09 | 0.29 | 999.99 | 498 |
| 2025-07-28 | IMAB | 1.86 | 0.30 | 4.50 | 499 |
| 2025-07-29 | IMAB | 1.68 | 0.32 | 0.00 | 510 |
| 2025-07-30 | IMAB | 2 | 0.31 | 0.05 | 514 |
| 2025-07-31 | IMAB | 2.01 | 0.25 | 0.02 | 635 |
| 2025-08-01 | IMAB | 2.62 | 0.22 | 0.23 | 690 |
| 2025-08-04 | IMAB | 2.89 | 0.21 | 0.08 | 3380 |
| 2025-08-05 | IMAB | 3.38 | 0.23 | 0.06 | 3493 |
| 2025-08-06 | IMAB | 3.72 | 0.24 | 0.06 | 3802 |
| 2025-08-07 | IMAB | 3.58 | 0.22 | 0.06 | 4613 |
| 2025-08-08 | IMAB | 3.42 | 0.21 | 0.00 | 4847 |
| 2025-08-11 | IMAB | 3.88 | 0.21 | 0.12 | 4960 |
| 2025-08-12 | IMAB | 3.82 | 0.21 | 0.24 | 4999 |
| 2025-08-13 | IMAB | 4.26 | 0.22 | 0.12 | 4959 |
| 2025-08-14 | IMAB | 5.22 | 0.21 | 0.04 | 5131 |
| 2025-08-15 | IMAB | 4.86 | 0.22 | 0.15 | 5569 |
| 2025-08-18 | IMAB | 5.12 | 0.19 | 0.17 | 3868 |
| 2025-08-19 | IMAB | 4.27 | 0.19 | 0.32 | 3967 |
| 2025-08-20 | IMAB | 4.55 | 0.20 | 0.05 | 4285 |
| 2025-08-21 | IMAB | 4.73 | 0.19 | 0.04 | 4516 |
| 2025-08-22 | IMAB | 5.11 | 0.19 | 0.03 | 4534 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | IMAB | 2.11 | - | - | -0.20 |
| 2025-07-28 | IMAB | 1.86 | - | - | -0.20 |
| 2025-07-29 | IMAB | 1.70 | - | - | -0.20 |
| 2025-07-30 | IMAB | 2.03 | - | - | -0.20 |
| 2025-07-31 | IMAB | 2.01 | - | - | -0.20 |
| 2025-08-01 | IMAB | 2.62 | - | - | -0.20 |
| 2025-08-04 | IMAB | 2.93 | - | - | -0.20 |
| 2025-08-05 | IMAB | 3.37 | - | - | -0.20 |
| 2025-08-06 | IMAB | 3.71 | - | - | -0.20 |
| 2025-08-07 | IMAB | 3.51 | - | - | -0.20 |
| 2025-08-08 | IMAB | 3.41 | - | - | -0.20 |
| 2025-08-11 | IMAB | 3.88 | - | - | -0.20 |
| 2025-08-12 | IMAB | 3.82 | - | - | -0.20 |
| 2025-08-13 | IMAB | 4.24 | - | - | -0.20 |
| 2025-08-14 | IMAB | 5.21 | - | - | -0.20 |
| 2025-08-15 | IMAB | 4.85 | - | - | -0.20 |
| 2025-08-18 | IMAB | 5.09 | - | - | -0.20 |
| 2025-08-19 | IMAB | 4.21 | - | - | -0.20 |
| 2025-08-20 | IMAB | 4.49 | - | - | -0.20 |
| 2025-08-21 | IMAB | 4.72 | - | - | -0.20 |
| 2025-08-22 | IMAB | 5.18 | - | - | -0.23 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | IMAB | 0.00 | -43.46 | 0.76 |
| 2025-07-28 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-07-29 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-07-30 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-07-31 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-08-01 | IMAB | 0.00 | -42.01 | 0.76 |
| 2025-08-04 | IMAB | 0.00 | -42.16 | 0.76 |
| 2025-08-05 | IMAB | 0.00 | -42.16 | 0.76 |
| 2025-08-06 | IMAB | 0.00 | -42.16 | 0.76 |
| 2025-08-07 | IMAB | 0.00 | -42.16 | 0.76 |
| 2025-08-08 | IMAB | 0.00 | -42.16 | 0.94 |
| 2025-08-11 | IMAB | 0.00 | -35.70 | 0.94 |
| 2025-08-12 | IMAB | 0.00 | -35.70 | 0.80 |
| 2025-08-13 | IMAB | 0.00 | -35.70 | 0.80 |
| 2025-08-14 | IMAB | 0.00 | -35.70 | 0.80 |
| 2025-08-15 | IMAB | 0.00 | -35.70 | 0.80 |
| 2025-08-18 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-19 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-20 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-21 | IMAB | 0.00 | -29.53 | 0.80 |
| 2025-08-22 | IMAB | 0.00 | -29.53 | 0.80 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
Institutional Transactions
-29.53
Beta
1.23
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
15
Growth Score
18
Sentiment Score
84
Actual DrawDown %
93.9
Max Drawdown 5-Year %
-99.3
Target Price
6.2
P/E
Forward P/E
PEG
P/S
P/B
2.05
P/Free Cash Flow
EPS
-0.71
Average EPS Est. Cur. Y
-0.23
EPS Next Y. (Est.)
-0.33
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.8
Return on Equity vs Sector %
-29.3
Return on Equity vs Industry %
-16.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
I-MABSector: Healthcare
Industry: Biotechnology
Employees: 32
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
stock quote shares IMAB – I-Mab ADR Stock Price stock today
news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMAB – I-Mab ADR yahoo finance google finance
stock history IMAB – I-Mab ADR invest stock market
stock prices IMAB premarket after hours
ticker IMAB fair value insiders trading